'Cutting-edge science': OCD drug designed by artificial intelligence

Two pharmaceutical companies have embarked on a brave new world, having begun human testing for the first time on a drug treatment for obsessive-compulsive disorder designed by artificial intelligence. British startup Exscientia and Japan's Sumitomo Dainippon Pharma used artificial intelligence to create the drug in less than 12 months, cutting four years from the average time it takes ordinary humans to develop a medication. Exscientia CEO Andrew Hopkins described the clinical human trial of the drug -- a molecule called DSP-1181 -- as a "key milestone in drug discovery." TOP STORIES Milwaukee teacher placed on leave after praising Rush Limbaugh's cancer diagnosis Impeachment 2.0? "Our driving motivation is to accelerate the range of innovative drugs from cutting-edge science entering into the clinic to increase the treatment options for patients. That means reducing the time to make and test a drug. The consumer should see benefits from faster progress to the clinic," Mr. Hopkins told The Washington Times.